We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

112 hedge funds and large institutions have $407M invested in UroGen Pharma in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

26% more call options, than puts

Call options by funds: $920K | Put options by funds: $728K

24% more capital invested

Capital invested by funds: $328M → $407M (+$79.4M)

8.79% more ownership

Funds ownership: 70.82% → 79.61% (+8.8%)

7% more funds holding

Funds holding: 105 → 112 (+7)

14% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 36

Holders
112
Holders Change
+7
Holders Change %
+6.67%
% of All Funds
1.61%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
20
Increased
31
Reduced
36
Closed
13
Calls
$920K
Puts
$728K
Net Calls
+$192K
Net Calls Change
+$184K

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$26.6M
2
RI
RTW Investments
New York
+$25M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$21.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$16.1M
5
JFG
Jefferies Financial Group
New York
+$13.7M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$8.49M
2
Millennium Management
Millennium Management
New York
-$6.29M
3
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$3.21M
4
Cerity Partners
Cerity Partners
New York
-$1.44M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.37M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
26
ARK Investment Management
Florida
$2.19M -$248K -15,196 -9%
AA
27
AlphaCentric Advisors
Puerto Rico
$2.16M -$181K -11,102 -7%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$2.05M +$525K +32,141 +31%
Goldman Sachs
29
Goldman Sachs
New York
$1.71M -$5.87K -359 -0.3%
SSA
30
Schonfeld Strategic Advisors
New York
$1.56M -$454K -27,800 -21%
N
31
Nuveen
North Carolina
$1.25M – – –
AC
32
Annandale Capital
Texas
$1.22M -$4.56K -279 -0.3%
Two Sigma Investments
33
Two Sigma Investments
New York
$1.21M -$821K -50,258 -38%
DLP
34
De Lisle Partners
United Kingdom
$1.15M +$1.26M +77,093 New
CWM
35
CIBC World Markets
New York
$1.13M +$1.23M +75,000 New
Citadel Advisors
36
Citadel Advisors
Florida
$1.08M -$1.18M -72,063 -50%
Ameriprise
37
Ameriprise
Minnesota
$1.06M -$32.8K -2,009 -3%
RHJA
38
Rice Hall James & Associates
California
$1.06M +$8.4K +514 +0.7%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.02M -$30.8K -1,885 -3%
Squarepoint
40
Squarepoint
New York
$946K +$54.7K +3,349 +6%
Charles Schwab
41
Charles Schwab
California
$943K – – –
ORI
42
Oak Ridge Investments
Illinois
$918K +$1M +61,204 New
Bank of America
43
Bank of America
North Carolina
$796K -$304K -18,601 -26%
HSBC Holdings
44
HSBC Holdings
United Kingdom
$794K +$866K +52,954 New
AI
45
Atom Investors
Texas
$747K -$170K -10,375 -17%
UBS Group
46
UBS Group
Switzerland
$643K +$291K +17,798 +71%
AQR Capital Management
47
AQR Capital Management
Connecticut
$634K +$390K +23,879 +130%
Millennium Management
48
Millennium Management
New York
$628K -$6.29M -384,626 -90%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$597K +$275K +16,799 +73%
CBA
50
Coastal Bridge Advisors
Connecticut
$555K -$12.3K -750 -2%
1
2
3 4 5

URGN Hedge Fund Activity: Q1 2024 in Review

112 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2024, worth a combined $407M — up 24% from $328M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new URGN positions and 13 closed out — a net gain of 7 holders — while 31 added to existing stakes and 36 trimmed.

The largest buyer was Cowen and Company, opening a new position worth an estimated $26.6M. The largest seller was Morgan Stanley, cutting an estimated $8.49M.

  • 112 institutional investors held UroGen Pharma (URGN) as of Q1 2024, up from 105 in Q4 2023.
  • Funds reported $407M of UroGen Pharma stock for Q1 2024, up 24% quarter-over-quarter.
  • 20 funds opened new UroGen Pharma positions in Q1 2024 and 13 closed out, a net change of +7 holders.
  • The largest UroGen Pharma buyer in Q1 2024 was Cowen and Company, an estimated $26.6M added.
  • The largest UroGen Pharma seller in Q1 2024 was Morgan Stanley, an estimated $8.49M sold.

Based on aggregated 13F filings for Q1 2024.